11-08-2025 | Pfizer’s bold acquisition, falling U.S. confidence, and tech market turbulence mark a pivotal economic moment.

Companies: Pfizers ten billion dollar move for Metsera. The pharmaceutical giant reached an agreement to acquire Metsera, securing access to its promising obesity drug pipeline; the deal follows intense competition among major drugmakers seeking leadership in the fast-growing weight-loss treatment market. The transaction still requires regulatory approval but positions Pfizer to regain momentum after recent revenue declines in its vaccine business. The Economy: United States consumer sentiment hits three-year low. American households grew more pessimistic in early November, with surveys showing widespread concern about the economy amid a prolonged government shutdown; short-term inflation expectations rose slightly while longer-term forecasts eased. Economists warn that the lack of official data releases may hinder economic planning and deepen uncertainty in the weeks ahead. Markets: Nasdaq slides as technology stocks retreat. The Nasdaq recorded its steepest weekly loss since April, driven by profit-taking and valuation concerns in artificial-intelligence-linked technology firms; investors grew cautious as rising yields and volatile trading pressured growth shares. Market analysts pointed to renewed sensitivity around earnings expectations and shifting sentiment in the broader United States equity landscape. Innovation: Microsoft launches superintelligence research team. The company formed the MAI Superintelligence Team, led by Mustafa Suleyman, to pursue advanced artificial intelligence models focused on human-centered design; initial work targets medical diagnostics and specialized systems. Microsoft said the initiative reflects a long-term investment in next-generation artificial intelligence.